News & Updates

Gout patients have about sixfold greater odds of experiencing a flare in the first few months after COVID-19 vaccination, but colchicine appears to keep these gout attacks at bay, as shown in a study from China.

The novel topical nonsteroidal anti-inflammatory drug (NSAID) S-flurbiprofen plaster provides relief from pain that appears similar to that achieved with diclofenac gel in patients with knee osteoarthritis, in addition to being well tolerated, according to data from an open-label, noninferiority phase III study.

Deucravacitinib, a selective TYK2 inhibitor, is well tolerated and appears to produce marked improvements in American College of Rheumatology 20 (ACR20) and other endpoints in the treatment of patients with psoriatic arthritis (PsA), according to the results of a phase II study.

No apparent association exists between neuropsychiatric systemic lupus erythematosus (NPSLE) and known risk loci for schizophrenia in a multiethnic cohort of patients with childhood-onset (c)SLE, reveals a recent study.

Sarcoidosis patients with biopsy-verified non-necrotizing granulomatous inflammation are at greater risk of haematologic cancers and nonmelanoma skin cancer (NMSC) in the long term than the general population, a study has found.

Treatment with oral baricitinib steadily inhibits radiographic progression of structural joint damage in most patients with rheumatoid arthritis (RA), while achieving clinical improvement in disease activity, through 5 years as compared with initial conventional synthetic disease-modifying antirheumatic drug (csDMARD) or placebo, results of a study have shown.

Patients with psoriatic arthritis (PsA) do not appear to be at increased risk of mortality from all causes, reveals a study. Moreover, the specific proportionate mortality rate (PMR) in this cohort is similar to that of the general population.